In recent years we have not only learned about new therapy options to slow down cyst growth in ADPKD. PROPKD, a progression score which combines clinical with genetic data, has been validated, which is a tool for the nephrologist in making individual clinical decisions in favour or against (potentially harmful) long-term medications. Patient cohorts have been characterized in whom kidney size remains stable at a certain plateau for years. This article reviews the literature on these new options and discusses possible adjustments of the PROPKD score and treatment options specifically for East Asian patients. Also, a practical concept for the clinic is proposed regarding the best management of CKD patients with ADPKD, making use of the progression score and pharmacogenetic information.
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : July 15, 2019